Boston Biomedical: Our History and Achievements
Boston Biomedical was founded in 2006 by Chiang J. Li, MD, FACP. Over the next several years, our founding researchers established Boston Biomedical as a leader in the emerging field of therapeutics focusing on cancer stem cell pathways. Today, we continue at the forefront of this area of research and development with multiple compounds in our pipeline.
Boston Biomedical was acquired by Sumitomo Dainippon Pharma of Osaka, Japan in April 2012. With greater resources and a global reach, we have expanded our R&D program, grown our portfolio of investigational compounds, and established a strong commercial operations infrastructure.
With the 2013 move to new corporate headquarters in Cambridge, Massachusetts, we aim to leverage our renowned scientific excellence and leadership to advance the development of novel cancer therapeutics. We continue to expand our research capabilities and commercial operations at Boston Biomedical.
BB503 (also known as BBI503 or BBI-503) will now be referred to under the generic name amcasertib
BB608 (also known as BBI608) will now be referred to under the generic name napabucasin
More than 20 clinical programs underway
BB608 enters Phase III clinical development
Boston Biomedical Headquarters and Sumitomo Dainippon Pharma Global Oncology Office open in Cambridge, MA
Boston Biomedical acquired by Sumitomo Dainippon Pharma
BB503™ (also known as BBI503 or BBI-503) enters clinical trials
Product Option License Agreement with Sumitomo Dainippon Pharma and Boston Biomedical for BB608
aiRNA technology published in Nature Biotechnology
Boston Biomedical begins independent operations
Boston Biomedical is incorporated
Chiang J. Li, MD, elected Fellow of the National Academy of Inventors
Boston Biomedical selected for “Ambassador” panel at Governor Patrick’s forum on “Strengthening our Global Ties to Create Growth + Opportunity in Massachusetts.”
Boston Biomedical named “Company To Watch” in the 10th Annual Team Massachusetts Economic Impact Awards.
BBI608 selected as one of the world’s Top Ten Cancer Drugs in Late Stage Clinical Development (Fierce Biotech).
Boston Biomedical ranked the most capital efficient company of the year, and deemed one of the most capital efficient biotechs in history (Venture Capital Journal).
Boston Biomedical recognized as Oncology Pioneer (Alexandria Oncology Summit).
Boston Biomedical selected as the sole healthcare industry recipient of the Frost & Sullivan 2010 North American Drug Discovery Technology Innovation of the Year Award.
BBI608 Phase I late-breaking abstract for the American Association of Cancer Research (AACR) annual meeting highlighted in a special meeting press release.
Boston Biomedical received a National Cancer Institute Cancer Stem Cells Initiative award in a nation-wide competition.